Novartis faces $1.9B hit from Avidity fail but maintains confidence in $12B buy

Novartis remains “very happy” with its $12 billion acquisition of Avidity Biosciences, despite a Phase 3 disappointment for the antibody-oligonucleotide conjugate del-desiran.